Veterinary Medicines Information website

Vectormune HVT-AIV Concentrate and solvent for suspension for injection

Authorised
  • Turkey herpesvirus, strain rHVT/AI-H5 (FC126, cell-associated), expressing haemagglutinin gene of Avian influenza virus subtype H5, Live
Download as PDF

Product identification

Medicine name:
Vectormune HVT-AIV Concentrate and solvent for suspension for injection
Active substance:
  • Turkey herpesvirus, strain rHVT/AI-H5 (FC126, cell-associated), expressing haemagglutinin gene of Avian influenza virus subtype H5, Live
Target species:
  • Chicken (one day-old chick)
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Turkey herpesvirus, strain rHVT/AI-H5 (FC126, cell-associated), expressing haemagglutinin gene of Avian influenza virus subtype H5, Live
    Presentation_strength:2 500 – 12 000 PFU/dose Reference:HSE Index:0
Pharmaceutical form:
  • Concentrate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Chicken (one day-old chick)
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Package description:
  • Packaging:Ampoule (glass), Package_size:1 ampoule, Content:4000 doses
  • Packaging:Ampoule (glass), Package_size:1 ampoule, Content:2000 doses
  • Packaging:Ampoule (glass), Package_size:1 ampoule, Content:1000 doses

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Applications in exceptional circumstances (Article 25 of Regulation (EU) 2019/6)
Marketing authorisation holder:
  • Ceva Sante Animale
Marketing authorisation date:
Manufacturing sites for batch release:
  • Ceva-Phylaxia Zrt.
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

English (PDF)
Published on: 8/07/2026
Download
Finnish (PDF)
Published on: 8/07/2026
Download
French (PDF)
Published on: 8/07/2026
Download
Croatian (PDF)
Published on: 8/07/2026
Download
Hungarian (PDF)
Published on: 8/07/2026
Download
Icelandic (PDF)
Published on: 8/07/2026
Download
Italian (PDF)
Published on: 8/07/2026
Download
Lithuanian (PDF)
Published on: 8/07/2026
Download
Latvian (PDF)
Published on: 8/07/2026
Download
Maltese (PDF)
Published on: 8/07/2026
Download
Dutch (PDF)
Published on: 8/07/2026
Download
Polish (PDF)
Published on: 8/07/2026
Download
Norwegian (PDF)
Published on: 8/07/2026
Download
Portuguese (PDF)
Published on: 8/07/2026
Download
Romanian (PDF)
Published on: 8/07/2026
Download
Slovak (PDF)
Published on: 8/07/2026
Download
Slovenian (PDF)
Published on: 8/07/2026
Download
Swedish (PDF)
Published on: 8/07/2026
Download
Bulgarian (PDF)
Published on: 8/07/2026
Download
Danish (PDF)
Published on: 8/07/2026
Download
German (PDF)
Published on: 8/07/2026
Download
Greek (PDF)
Published on: 8/07/2026
Download
Czech (PDF)
Published on: 8/07/2026
Download
Estonian (PDF)
Published on: 8/07/2026
Download
Spanish (PDF)
Published on: 8/07/2026
Download

ema-puar-v6288-vectormunehvtaiv-initial-en.pdf

English (PDF)
Published on: 12/09/2025
Download